XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 81 Months Ended
Aug. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2019
USD ($)
performanceObligation
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2022
USD ($)
Collaboration And Other Agreements [Line Items]                          
Revenues       $ 110,708 $ 10,397 $ 130,609 $ 48,029            
Deferred revenue, current       23,308   23,308         $ 23,308 $ 21,651  
Deferred revenue, net of current portion       55,503   55,503         55,503 59,243  
Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment                 $ 150,000        
Potential commercial milestone payments under agreement               $ 330,000          
Potential development and regulatory milestone payments under agreement               210,000          
Development and regulatory milestones recognized $ 100,000                   215,000    
Collaborative agreement transaction price               $ 154,000          
Variable consideration recognized                   $ 4,000      
Number of performance obligations | performanceObligation               2          
Gilead | Gilead First Research Program                          
Collaboration And Other Agreements [Line Items]                          
Revenues   $ 3,300   400 100 2,400 100            
Deferred revenue       16,400   16,400         16,400 14,900  
Deferred revenue, current       16,400   16,400         16,400 11,800  
Deferred revenue, net of current portion                       3,100  
Minimum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)               15.00%          
Maximum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)               24.00%          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Revenues       100 15,000 300 15,000   $ 150,000        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                          
Collaboration And Other Agreements [Line Items]                          
Revenues         200 100 1,700            
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                          
Collaboration And Other Agreements [Line Items]                          
Revenues       500 100 1,400 300            
RevenuesFromCMOAgreementsMember | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment     $ 10,000                    
Annual Fixed Payments     $ 14,400                    
Revenues       3,800 $ 4,500 8,100 $ 9,600            
Deferred revenue       4,600   4,600         4,600 7,000  
Deferred revenue, current       $ 4,600   $ 4,600         $ 4,600 $ 7,000  
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Annual Fixed Payments                         $ 19,500
Additional Payments                         $ 5,100
Manufacturing Services | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Extension term                         1 year
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                          
Collaboration And Other Agreements [Line Items]                          
Revenue, remaining performance obligation, expected timing of satisfaction     3 years